CRIS Current Research Information System

BOLONDI, LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 20.923
AS - Asia 16.452
EU - Europa 13.547
AF - Africa 1.047
SA - Sud America 981
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 28
Totale 53.007
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.695
VN - Vietnam 5.118
SG - Singapore 4.322
CN - Cina 3.813
GB - Regno Unito 3.434
IT - Italia 1.946
DE - Germania 1.826
SE - Svezia 1.503
HK - Hong Kong 1.076
FR - Francia 940
UA - Ucraina 800
IN - India 780
RU - Federazione Russa 756
BR - Brasile 669
IE - Irlanda 537
NL - Olanda 384
FI - Finlandia 336
ZA - Sudafrica 321
JP - Giappone 304
EE - Estonia 259
TG - Togo 256
CH - Svizzera 249
CI - Costa d'Avorio 216
BD - Bangladesh 147
BG - Bulgaria 139
CA - Canada 137
JO - Giordania 137
KR - Corea 131
PH - Filippine 114
AR - Argentina 106
SC - Seychelles 95
BE - Belgio 85
NG - Nigeria 70
TH - Thailandia 70
EC - Ecuador 67
ID - Indonesia 63
IQ - Iraq 62
PL - Polonia 57
MX - Messico 54
AT - Austria 48
GR - Grecia 42
ES - Italia 41
IR - Iran 39
TW - Taiwan 39
TR - Turchia 37
CL - Cile 36
HR - Croazia 33
PK - Pakistan 30
RO - Romania 30
CO - Colombia 29
UZ - Uzbekistan 25
LT - Lituania 24
SA - Arabia Saudita 24
EU - Europa 21
MY - Malesia 20
PE - Perù 20
AU - Australia 19
LB - Libano 19
MA - Marocco 19
PY - Paraguay 16
VE - Venezuela 16
HU - Ungheria 14
EG - Egitto 13
AE - Emirati Arabi Uniti 12
UY - Uruguay 12
KE - Kenya 11
OM - Oman 11
MK - Macedonia 10
CR - Costa Rica 9
ET - Etiopia 9
AM - Armenia 8
TN - Tunisia 8
BO - Bolivia 7
CZ - Repubblica Ceca 7
DO - Repubblica Dominicana 7
IL - Israele 7
NP - Nepal 7
NZ - Nuova Zelanda 7
JM - Giamaica 6
KZ - Kazakistan 6
MD - Moldavia 6
A2 - ???statistics.table.value.countryCode.A2??? 5
AL - Albania 5
DZ - Algeria 5
NO - Norvegia 5
PT - Portogallo 5
RS - Serbia 5
AZ - Azerbaigian 4
DK - Danimarca 4
MU - Mauritius 4
PR - Porto Rico 4
SI - Slovenia 4
SN - Senegal 4
SY - Repubblica araba siriana 4
BA - Bosnia-Erzegovina 3
BH - Bahrain 3
CG - Congo 3
GE - Georgia 3
GH - Ghana 3
QA - Qatar 3
Totale 52.954
Salva come PNG Salva come JPEG
Città #
Southend 3.061
Singapore 2.972
Ashburn 2.203
Fairfield 2.111
Chandler 1.501
Dong Ket 1.265
San Jose 1.066
Houston 1.019
Hong Kong 1.015
Wilmington 993
Woodbridge 982
Ho Chi Minh City 926
Seattle 891
Hanoi 785
Santa Clara 780
Ann Arbor 731
Cambridge 685
Princeton 676
Dublin 534
Jacksonville 522
Beijing 491
Boardman 428
Lauterbourg 338
Bologna 326
Westminster 312
Nanjing 309
Helsinki 296
Hefei 280
Padova 274
Los Angeles 269
Tokyo 266
Lomé 256
Munich 254
Berlin 217
Abidjan 216
Bern 213
Council Bluffs 199
New York 190
Dallas 173
Jinan 162
Buffalo 160
Saint Petersburg 159
Shenyang 141
Haiphong 140
Sofia 139
Amman 135
Da Nang 135
Milan 126
Nanchang 118
San Diego 109
Guangzhou 108
Changsha 106
Frankfurt am Main 105
Turin 104
Medford 103
Shanghai 100
Hebei 94
São Paulo 92
Redondo Beach 91
Mülheim 85
Tianjin 84
Brussels 79
Florence 78
Seoul 78
Dearborn 75
Zhengzhou 70
Abeokuta 66
Chicago 65
Rome 62
Jiaxing 58
Bremen 50
Falls Church 50
Mahé 50
Phoenix 50
Des Moines 48
London 48
Ningbo 47
Norwalk 46
Redmond 46
Orem 45
Olalla 44
Toronto 44
Hangzhou 43
Redwood City 43
The Dalles 43
Hải Dương 42
Amsterdam 41
Can Tho 39
Montreal 39
Falkenstein 37
Yubileyny 36
Haikou 35
Wuhan 35
Paris 34
Johannesburg 33
Thái Nguyên 33
Verona 33
Bühl 32
Biên Hòa 31
Mountain View 31
Totale 34.480
Salva come PNG Salva come JPEG
Nome #
Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study 481
Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study 433
Molecular Adsorbent Recirculating System (MARS) application in liver failure: Clinical and hemodepurative results in 22 patients 404
Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study 364
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 326
Efficacy of radioembolization according to tumor morphology and portal vein thrombosis inintermediate-advanced hepatocellular carcinoma 315
Impiego del MARS nell'insufficienza epatica: efficacia depurativa e risultati clinici in 22 pazienti 306
Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study 287
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 287
A modeling study of bilirubin kinetics during Molecular Adsorbent Recirculating System sessions. 286
Circulating microRNAs, MIR-939, MIR-595, MIR-519d and MIR-494, identify cirrhotic patients with HCC 286
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 271
Accuracy of VirtualTouch Acoustic Radiation Force Impulse (ARFI) imaging for the diagnosis of cirrhosis during liver ultrasonography 264
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. 262
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis 261
Acute systemic, splanchnic and renal haemodynamic changes induced by molecular adsorbent recirculating system (MARS) treatment in patients with end-stage cirrhosis. 254
A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system. 254
Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma 254
Ablazione percutanea ecoguidata mediante radiofrequenza di piccoli noduli di HCC: fattori correlati all'esito clinico e alla recidiva di malattia 245
Platelet count does not predict bleeding in cirrhotic patients: Results from the PRO-LIVER Study 242
Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. 240
Venom from Cuban Blue Scorpion has tumor activating effect in hepatocellular carcinoma 237
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 236
Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted? 234
Use of perfusional angiosonography in liver transplantation and conservative management of post-transplant intra-hepatic pseudo-aneurysm. 233
Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. 231
Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis 225
Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. 224
LncRNAs as novel players in hepatocellular carcinoma recurrence 224
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 221
Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. 219
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. 219
A new mathematical model for bilirubin kinetics during MARS sessions 218
Enhanced uptake of lactosaminated human albumin by rat hepatocarcinomas: implications for an improved chemotherapy of primary liver tumors. 217
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 216
Corrigendum: Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma (Scientific Reports (2017) 7 (44685) DOI: 10.1038/srep44685) 215
Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma. 215
Nozioni di ecografia Doppler e color-Doppler 214
Reliability of imaging techniques in assessing portal venous thrombosis in patients with hepatocellular carcinoma candidates for liver transplantation 214
Affidabilità della combinazione di angioecografia perfusionale ed altre tecniche di imaging nella valutazione della trombosi portale in pazienti con epatocarcinoma (HCC) candidati al trapianto di fegato 213
Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatments and outcome. 212
Comparison of International Guidelines for Noninvasive Diagnosis of Hepatocellular Carcinoma 211
A case of inflammatory ascites. 211
Extracorporeal Detoxification for Hepatic Failure Using Molecular Adsorbent Recirculating System: Depurative Efficiency and Clinical Results in a Long-Term Follow-Up 210
Implementation of the Frailty Index in hospitalized older patients: Results from the REPOSI register 210
Analysis of risk factors for early hepatic artery thrombosis after liver transplantation. Possible contribution of reperfusion in the early morning. 208
Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma 208
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA. database 208
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 207
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 206
Celiac disease diagnosed through screening programs in at-risk adults is not associated with worse adherence to the gluten-free diet and might protect from osteopenia/osteoporosis 206
The rational use of albumin in patients with cirrhosis and ascites. A Delphi study for the attainment of a consensus on prescribing standards. 205
Artificial neural network is superior to MELD in predicting mortality of patients with end-stage liver disease. 205
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma 205
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. 203
Assessment of liver fibrosis in trnsplant recipients with recurrent HCV infection: Usefulness of transient elastography. 203
Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma 202
Impiego clinico del “Fegato Artificiale” MARS: effetti sulle citochine e sui fattori di crescita 201
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. 200
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 199
Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study 198
Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry 198
Basi scientifiche per la definizione delle linee guida in ambito clinico per l’epatocarcinoma. 197
Quantification of enhancement of focal liver lesions during contrast-enhanced ultrasound (CEUS). Analysis of ten selected frames is more simple but as reliable as the analysis of the entire loop for most parameters. 197
Clinical and diagnostic aspects of gluten related disorders 197
Thorough assessment of portal venous thrombosis in patients with HCC allows adequate selection of candidates for liver transplantation 197
Linee guida A.I.S.F. per l'ipertensione portale. 196
Efficacy of doxorubicin coupled to lactosaminated albumin on rat hepatocellular carcinomas evaluated by ultrasound imaging. 196
Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma 196
Conditional survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. 196
Doxorubicin coupled to lactosaminated albumin: effect of heterogeneity in drug load on conjugate disposition and hepatocellular carcinoma uptake in rats. 195
A case of intractable pruritus in Turner's syndrome successfully treated with molecular adsorbent recirculating system. 195
Contrast-enhanced ultrasonography features of extramedullary hematopoiesis presenting as a presacral mass: an update of the literature. 195
A conjugate of doxorubicin with lactosaminated albumin enhances the drug concentrations in all the forms of rat hepatocellular carcinomas independently of their differentation grade. 194
Corrigendum to “Differences in liver stiffness values obtained with new ultrasound elastography machines and fibroscan: A comparative study” [Dig. Liver Dis. 49 (2017) 802–808](S1590865817302463)(10.1016/j.dld.2017.03.001) 194
Clinical application of artificial liver support with the Molecular Adsorbent Recirculating System (MARS): impact on cytokines and growth factors 194
Detoxification of bilirubin and bile acids with intermittent coupled plasmafiltration and adsorption in liver failure (HERCOLE study) 193
Contrast-enhanced ultrasonography to diagnose complicated acute cholecystitis 192
Characterization of focal liver lesions with contrast-enhanced ultrasound. 190
ASSOCIATIONS OF THE -174 G/C INTERLEUKIN-6 GENE PROMOTER POLYMORPHISM WITH SERUM INTERLEUKIN -6 AND MORTALITY IN THE ELDERLY 190
Binding of the doxorubicin-lactosaminated human albumin conjugate to HCC cells is mediated by the drug moieties. 190
Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. 189
In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. 189
Stadiazione epatica dei carcinomi gastrointestinali di prima diagnosi mediante angioecografia perfusionale. Confronto con TC spirale ed ecografia convenzionale. 188
Diagnostic features of real-time contrast-enhanced ultrasound in focal nodular hyperplasia of the liver. 188
CDKN1C/P57 Is Regulated by the Notch Target Gene Hes1 and Induces Senescence in Human Hepatocellular Carcinoma. 188
A relative deficiency of lysosomal acid lypase activity characterizes non-alcoholic fatty liver disease 186
Characterization of Small Nodules (1-3 cm) in Cirrhosis. The role of Perfusional Angiosonography, Spiral Computed Tomography and Double Contrast Magnetic Resonance 186
Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. 186
Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer 185
Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. 185
Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. 185
Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging 185
Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma. 185
Prognostic value of degree and types of anaemia on clinical outcomes for hospitalised older patients 184
DIAGNOSTIC ACCURACY OF LIVER AND SPLEEN STIFFNESS MEASUREMENT FOR PORTAL HYPERTENSION USING BIDIMENSIONAL SHEAR WEAVE ELASTOGRAPHY 184
Different haemodynamic effects of a single dose of long-acting isosorbide-5-mononitrate in healthy subjects and patients with cirrhotic portal hypertension. 183
The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma 183
Doxorubicin coupled to lactosaminated human albumin: a hepatocellular carcinoma targeted drug. 182
Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study. 180
Totale 22.278
Salva come PNG Salva come JPEG
Categoria #
all - tutte 142.779
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 142.779
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.825 0 0 0 0 0 0 0 0 0 0 0 1.825
2021/20226.466 775 251 385 523 573 373 153 376 206 370 1.505 976
2022/20236.532 742 918 314 838 411 483 175 314 1.176 170 535 456
2023/20241.653 139 292 111 167 145 366 87 85 72 94 52 43
2024/20256.696 266 1.124 564 497 1.108 367 520 236 108 468 178 1.260
2025/202615.453 1.279 1.178 1.330 1.093 1.824 928 1.651 720 3.196 1.239 555 460
Totale 53.840